IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)

P. Emery; E. Keystone; H. P. Tony; A. Cantagrel; R. van Vollenhoven; A. Sanchez

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)

P. Emery
, E. Keystone
, H. P. Tony
, A. Cantagrel
, R. van Vollenhoven
, A. Sanchez

pre-AMC

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	296
Journal	Annals of the rheumatic diseases
Volume	68
Issue number	2
Publication status	Published - 2009
Externally published	Yes

Cite this

Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., & Sanchez, A. (2009). IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008). Annals of the rheumatic diseases, 68(2), 296.

Emery, P. ; Keystone, E. ; Tony, H. P. et al. / IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008). In: Annals of the rheumatic diseases. 2009 ; Vol. 68, No. 2. pp. 296.

@article{9756955a68e6405495576736947c2049,

title = "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)",

author = "P. Emery and E. Keystone and Tony, \{H. P.\} and A. Cantagrel and \{van Vollenhoven\}, R. and A. Sanchez",

year = "2009",

language = "English",

volume = "68",

pages = "296",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "2",

}

Emery, P, Keystone, E, Tony, HP, Cantagrel, A, van Vollenhoven, R & Sanchez, A 2009, 'IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)', Annals of the rheumatic diseases, vol. 68, no. 2, pp. 296.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008). / Emery, P.; Keystone, E.; Tony, H. P. et al.
In: Annals of the rheumatic diseases, Vol. 68, No. 2, 2009, p. 296.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)

AU - Emery, P.

AU - Keystone, E.

AU - Tony, H. P.

AU - Cantagrel, A.

AU - van Vollenhoven, R.

AU - Sanchez, A.

PY - 2009

Y1 - 2009

M3 - Comment/Letter to the editor

SN - 0003-4967

VL - 68

SP - 296

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 2

ER -

Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008). Annals of the rheumatic diseases. 2009;68(2):296.